- Open Access
In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation
© Kämpf et al.; licensee BioMed Central. 2015
- Received: 5 September 2014
- Accepted: 12 January 2015
- Published: 23 January 2015
Glycoconjugated vaccines composed of polysaccharide antigens covalently linked to immunogenic carrier proteins have proved to belong to the most effective and safest vaccines for combating bacterial pathogens. The functional transfer of the N-glycosylation machinery from Campylobacter jejuni to the standard prokaryotic host Escherichia coli established a novel bioconjugation methodology termed bacterial glycoengineering.
In this study, we report on the production of a new recombinant glycoconjugate vaccine against Shigella flexneri 2a representing the major serotype for global outbreaks of shigellosis. We demonstrate that S. flexneri 2a O-polysaccharides can be transferred to a detoxified variant of Pseudomonas aeruginosa carrier protein exotoxin A (EPA) by the C. jejuni oligosaccharyltransferase PglB, resulting in glycosylated EPA-2a. Moreover, we optimized the in vivo production of this novel vaccine by identification and quantitative analysis of critical process parameters for glycoprotein synthesis. It was found that sequential induction of oligosaccharyltransferase PglB and carrier protein EPA increased the specific productivity of EPA-2a by a factor of 1.6. Furthermore, by the addition of 10 g/L of the monosaccharide N-acetylglucosamine during induction, glycoconjugate vaccine yield was boosted up to 3.1-fold. The optimum concentration of Mg2+ ions for N-glycan transfer was determined to be 10 mM. Finally, optimized parameters were transferred to high cell density cultures with a 46-fold increase of overall yield of glycoconjugate compared to the one in initial shake flask production.
The present study is the first attempt to identify stimulating parameters for improved productivity of S. flexneri 2a bioconjugates. Optimization of glycosylation efficiency will ultimately foster the transfer of lab-scale expression to a cost-effective in vivo production process for a glycoconjugate vaccine against S. flexneri 2a in E. coli. This study is an important step towards this goal and provides a starting point for further optimization studies.
- Glycoconjugate vaccine
- Shigella flexneri 2a
- Process optimization
- High cell density culture
- Recombinant E. coli
Gram-negative, non-motile, enteroinvasive Shigella bacteria are human pathogens that cause severe infection known as shigellosis. The disease is estimated to affect 165 million people annually, leading to approximately 1.1 million deaths per year (WHO). Especially children under the age of five living in environments with poor sanitation and hygiene conditions bear an elevated risk to contract an infection [1,2]. Among the different Shigella serotypes S. flexneri 2a is the most widespread strain worldwide and responsible for most endemic outbreaks in developing countries .
Vaccination has been proven as a powerful strategy to combat infectious diseases like shigellosis. In the last years several different approaches have been developed to combat S. flexneri 2a, including vaccination with attenuated or heat-killed S. flexneri 2a strains [4,5], recombinant outer membrane proteins [6,7], subunit-based vaccines  and glycoconjugate vaccines . Particularly, conjugated vaccines composed of O-polysaccharide units of the lipopolysaccharide (LPS) covalently linked to immunogenic carrier proteins have attracted remarkable attention due to their inherent ability to evoke a T-cell dependent, long-lasting, serotype specific protective immunity. In contrary polysaccharide-only vaccines are often poor immunogens and elicit only T-cell independent, short-lived and low-affinity antibody responses [10,11]. It has already been demonstrated that glycoconjugates comprising O-specific polysaccharides of S. flexneri 2a covalently bound to Pseudomonas aeruginosa exoprotein A (EPA) are safe, immunogenic and efficacious in clinical phase III studies . However, broad applicability of glycoconjugated vaccines has been hindered by the complex production process which relies either on sophisticated chemical synthesis to obtain, activate and couple the oligosaccharide to the carrier protein  or on cultivation of the bacterial pathogen in large cultures to obtain the desired O-specific polysaccharides which constitutes a major health and safety issue. Furthermore, processing of the chemical conjugates is laborious and requires different purification steps accompanied by substantial loss of target material, resulting in a low efficiency and cost-effectiveness . Moreover, chemical crosslinking is highly unspecific, leading to low robustness and reproducibility of the production and consequently to difficulties in quality control of the vaccine.
Basic research of bacterial N-glycosylation resulted in the seminal discovery of the functional transfer of the Campylobacter jejuni N-glycosylation machinery in the standard prokaryotic host E. coli . Key enzyme of this recombinant technology is the C. jejuni oligosaccharyltransferase PglB. It exhibits relaxed substrate specificity towards glycans from different origins  and is able to link these polysaccharides covalently to target proteins (e.g. immunogenic carrier proteins) that contain specific N-glycosylation sites . Thereby tailor-made glycoconjugate vaccine candidates can be produced in non-toxic, engineered E. coli and purified in a simplified process from the bacterial periplasm as demonstrated recently for several polysaccharides of pathogens [17-20]. Depending on the polysaccharide substrate, there is a need for improving the glycosylation efficiency. Often a high percentage of the target protein remains unglycosylated, i.e., the glycoconjugate represents a small portion of the totally produced recombinant protein. A few studies describe the optimization of glycosylation efficiency by manipulation of the cellular metabolism [21-23].
In order to produce a more cost-effective vaccine for vaccination campaigns in developing countries, glycoconjugate yields can be optimized with respect to specific and volumetric productivity. High cell density cultivation (HCDC) of recombinant E. coli is a major strategy for maximizing volumetric productivity of recombinant proteins [24,25]. High cell densities can be reached by fed-batch cultivation, thereby reducing culture volume, enhancing biomass production and product recovery and hence reducing costs significantly. So far only one report describing a fed-batch bioprocess for in vivo production of a glycoconjugate vaccine against S. dysenteriae O1 in E. coli has been published .
In this study we report on (i) the establishment of an in vivo production system for the expression of a glycoconjugate vaccine against S. flexneri 2a in E. coli, (ii) the identification of critical parameters and cultivation conditions influencing the in vivo glycosylation efficiency and finally (iii) the transfer of the identified conditions to high cell density cultivations under controlled conditions to increase overall glycoconjugate yield. By applying a fed-batch process with the identified and optimized parameters the glycoconjugate yield was increased 46-fold compared to the shake flask cultures under non-optimized conditions.
In vivo glycosylation of EPA with S. flexneri 2a O-polysaccharides
Development of a reliable assay for quantification of glycoprotein
A prerequisite for optimization of glycoprotein yield is the availability of a reliable quantification method. In Figure 1A and 1B it was demonstrated that anti-EPA and anti-2a antibodies recognize EPA carrier and O-antigens, respectively. Therefore, we developed a sandwich enzyme-linked immunosorbent assay (ELISA) by coating high affinity 96-well plates with anti-EPA antibody as capture antibody and detecting bound glycoproteins from periplasmic fractions with anti-2a antibody (detection antibody). Appropriate dilutions of periplasmic extracts and antibody solutions were crucial to obtain high signal-to-noise ratios. Periplasmic samples from Figure 1A and Figure 1B were applied to the described ELISA format. The glycoprotein-containing sample resulted in a high readout at 450 nm while only negligible background signals were detected for the uninduced and PglBmut samples, thus reflecting the Western blot results accurately (Figure 1C). With the described ELISA configuration the relative yield of EPA-2a in periplasmic extracts obtained from different cultivation conditions could be easily compared on the same ELISA plate. However, absolute quantification is challenging because unglycosylated EPA is competing with EPA-2a for capture antibody binding sites. Hence, purified EPA-2a does not represent an appropriate standard for this approach.
Kinetics of EPA-2a production in shake flask and bioreactor
Induction strategy affects product yield
Induction strategies and influence on EPA-2a yield
Order of induction
Specific EPA-2a yield (A450 nm/OD 600 )
Sequential (1. EPA 2. PglB)
Sequential (1. PglB 2. EPA)
N-acetylglucosamine stimulates glycosylation efficiency
Involvement of Mg2+ ions on glycoprotein synthesis
Synergistic effect of sequential induction and addition of N-acetylglucosamine
Comparison of specific and volumetric EPA-2a yields in shake flask and high cell density cultivations
Type of cultivation
OD 600 at induction
Final OD 600
Specific yield (A450 nm/OD 600 )*
Volumetric yield (A450 nm/volume)
Bacterial glycoengineering enables the in vivo glycosylation of immunogenic carrier proteins with bacterial O-polysaccharides, thus providing a novel platform for the production of tailor-made glycoproteins as safe and effective vaccines against various pathogens. Thereby the expensive and sophisticated chemical synthesis and coupling process is circumvented and cost-effective vaccines for immunization campaigns for developing countries can be realized. The most widely used enzyme technology exploits the relaxed substrate specificity of the Campylobacter jejuni oligosaccharyltransferase PglB towards diverse lipid-linked polysaccharides [15,37,38]. The PglB system was recently applied to produce glycoconjugate vaccines against S. dysenteriae serotype O1, E. coli O121, Francisella tularensis and Brucella abortus [17-20,39]. In this study we report the bioconjugation of S. flexneri 2a polysaccharides to the well-established immunogenic carrier exotoxoid A of P. aeruginosa (EPA). The S. flexneri 2a repeating unit consists of three rhamnose residues and a GlcNAc at the reducing end, similarly to other Shigella and E. coli serotypes, e.g. S. dysenteriae type 1 and E. coli O7 oligosaccharide [40,41]. We could show that S. flexneri 2a O-polysaccharides are a substrate for PglB-mediated transfer to EPA and that the resulting glycoproteins were recognized by a specific antibody targeting S. flexneri 2a glycans. After establishing the S. flexneri 2a system, our study aimed at identifying critical parameters stimulating glycoconjugate yield. Analysis of samples at different time points post induction showed that maximum glycoconjugate yield per cell was obtained after 24 h, even though high amounts of EPA carrier protein were already present in the periplasm 1 h after induction. A similar observation was made when EPA-Shigella O1 glycoconjugates were produced in E. coli . This leads to the assumption that either PglB activity, O-polysaccharide assembly or polysaccharide precursor supply is rate-limiting. Induction time point and induction period plays a pivotal role in the expression of many recombinant proteins and the effectiveness of bioprocesses [42-44]. Upon addition of the inducer, overexpression of recombinant proteins consumes high amounts of essential biosynthetic precursors (e.g. amino acids, nucleotides). Thereby the cellular metabolism is negatively influenced which finally leads to multiple stress responses, reduced biomass formation and in turn to impaired recombinant protein expression [45-48]. Using the here described enzymatic protein glycan coupling technology, the situation is even more severe compared to the overexpression of single recombinant proteins. In this case, numerous components, i.e. oligosaccharyltransferase PglB, periplasmic protein carrier EPA and a whole set of enzymes required for lipid-linked O-polysaccharide synthesis have to be functionally expressed in a coordinate manner to enable maximum yield of the glycoconjugates. In the S. flexneri 2a system, the glycosyltransferase cluster was integrated in the host genome and constitutively expressed from its natural promoter. However, PglB oligosaccharyltransferase and EPA carrier protein were under control of the P tac and P araBAD promoters and were induced by IPTG and L-arabinose, respectively. The beneficial effect of sequential induction of PglB and EPA carrier expression observed in our study is probably related to the temporal separation of the overexpression of both components. This might relax the metabolic burden to some extent and allow a functional integration of PglB with its 13 transmembrane helices into the cell membrane by the precise interplay of translocases and insertases . A correctly inserted, functional PglB, which is already present at induction of carrier protein expression, presumably is able to better transfer Shigella flexneri 2a glycans to EPA during export of the carrier polypeptide to the periplasm, possibly before folding. In the case of simultaneous or opposite induction, a larger portion of EPA remains unglycosylated due to the absence of functional PglB immediately after induction.
We have shown in this study that the addition of N-acetylglucosamine increased the yield of EPA-2a significantly. N-acetylglucosamine (GlcNAc) is an acetylated glucosamine derivative and plays a key role at the bacterial cell surface. Besides, it is also an important signaling molecule . The first step in Shigella flexneri 2a O-polysaccharide assembly is the addition of one GlcNAc residue from the nucleotide activated sugar donor UDP-GlcNAc to the membrane-bound undecaprenyl pyrophosphate [51,52]. The UDP-GlcNAc is de novo synthesized in E. coli by the conversion of fructose-6-phosphate to glucosamine-6-phosphate , which is further processed by a glucosamine mutase to glucosamine-1-phosphate . Acetylation of the latter intermediate leads to formation of GlcNAc-1-phosphate, which is the substrate for the final uridyl transfer generating UDP-GlcNAc . It is assumed that synthesis of glucosamine-6-phosphate is the rate limiting step in UDP-GlcNAc synthesis . In contrast to eukaryotic cells, bacteria are not able to synthesize GlcNAc-6-phosphate. However, when N-acetylglucosamine is present in the culture medium, the N-acetylglucosamine transporter NagE in the inner membrane of E. coli imports GlcNAc to the cytosol where it is immediately phosphorylated by the phosphotransferase system (PTS) to form GlcNAc-6-phosphate . GlcNAc-6-phosphate is then converted via multiple enzymatic steps to GlcNAc-1-phosphate, which is finally activated by UTP to UDP-GlcNAc. Hence, the rate-limiting step of the de novo synthesis of glucosamine-6-phosphate is circumvented, which might result in an increased pool of the cytosolic activated sugar donor UDP-GlcNAc for glycan assembly and thus increase glycoprotein production. This hypothesis is supported by a recently published study, aiming at identifying genes beneficial for in vivo glycosylation of C. jejuni AcrA in a genome wide screen . Among five other identified genes, the bi-functional enzyme Dxs, an UDP-N-acetylglucosamine pyrophosphorylase/glucosamine-1-phosphatase involved in UDP-GlcNAc precursor synthesis was identified and led to 1.6 fold increased AcrA glycosylation . Interestingly, if GlcNAc was added to mammalian cells exogenously, it was also converted to UDP-GlcNAc, increasing the intracellular UDP-GlcNAc pool. The elevated level of UDP-GlcNAc is believed to result in enhanced N-glycan branching of glycosylated proteins in the Golgi apparatus .
In addition to the stimulating effect of N-acetylglucosamine, we found that Mg2+ ions are able to promote EPA-2a synthesis. Maximum EPA-2a yield was achieved by supplementation of the culture medium with 10 mM MgSO4. Divalent metal ions like Mg2+ and Mn2+ are essential co-factors for enzymatic reactions catalyzing the formation of phosphodiester bonds. The first reaction of the S. flexneri 2a O-polysaccharide assembly, the transfer of the GlcNAc moiety from UDP-GlcNAc to undecaprenyl pyrophosphate, is catalyzed by the integral membrane protein WecA in E. coli. In vitro assays with crude membrane extracts from overexpressing wecA E. coli cells demonstrated the absolute requirement of Mg2+ ions for the GlcNAc transfer . Purified WecA from T. maritima revealed a Mg2+ -dependent activity profile with a maximum at 10 mM and inhibitory effects with higher Mg2+ concentrations similar to our data . However, in contrast to the in vitro assay, EPA-2a was also produced in the absence of additional Mg2+ ions. This might be due to the complex medium components, yeast extract and soy peptone, in the culture medium which contain considerable amounts of metal ions. According to Liu et al. , the two glycosyltransferases WbgF and WbgG define the specific sequence of the repeating unit of the S. flexneri 2a O-polysaccharide by sequential addition of three rhamnose residues. The donor substrate for these glycosyltransferases is dTDP-rhamnose. Detailed biochemical characterization of WbgF and WbgG is lacking, so the requirement of divalent cations for their acitivity is speculative. The same holds true for GtrII, a glucosyltransferase attaching a glucose residue to rhamnose III, converting the repeating unit of S. flexneri serotype Y in 2a . There is a general agreement that metal ions are required for oligosaccharyltransferase activity in different organisms [34,62,63]. A recent study on PglB from Campylobacter lari demonstrated the requirement of either Mn2+ or Mg2+ for DQNAT sequon binding of acceptor peptides . It was shown that Mn2+ binds the acceptor with higher affinity than Mg2+, but this does not necessarily correlate with higher oligosaccharyltransferase catalytic activity. When essential amino acids (Asp-56 and Glu-319) involved in metal ion binding were mutated, glycosylation efficiency decreased dramatically and a double mutant was completely inactive . Although Mn2+ is supposed to be the physiological cation for PglB, we performed our experiments in the presence of different MgSO4 which is an essential component of the production media for high cell density cultivations . The increased EPA-2a yield in the presence of 10 mM MgSO4 might be generated by an overlapping effect of increased activity of involved glycosyltransferases (WecA, WbgF, WbgG) for O-polysaccharide assembly and enhanced catalytic activity of the oligosaccharyltransferase PglB. It would now be interesting to test whether the addition of extra Mn2+ also has a beneficial effect.
The present study is the first attempt to identify stimulating parameters for improved productivity of S. flexneri 2a bioconjugates. Three major factors were identified and quantitatively analyzed. A sequential induction strategy with a 2 hour gap between both inducer pulses, the addition of 10 g/L N-acetylglucosamine and the presence of 10 mM MgSO4 were favorable for EPA-2a production. By applying these parameters to high cell density cultures, EPA-2a yield was increased 46-fold compared to initial shake flask conditions. It is likely that these factors are not S. flexneri 2a specific but enable increased productivities also of other glycoconjugates with similar structural features, i.e. a GlcNAc residue at the reducing end. However, this needs to be analyzed in further studies. Optimization of glycosylation efficiency will ultimately foster the transfer of lab-scale expression to a cost-effective and reasonable in vivo production process for a glycoconjugate vaccine against S. flexneri 2a in E. coli. This study is an important step towards this goal and provides a starting point for further optimization studies.
Bacterial strains and plasmids
E. coli 1052 (W3110, F−, IN(rrnD-rrnE)1, rph 1, Δwbbl, ΔwbbJ, ΔwbbK, gtrS::gtrII, ΔwaaL, wb cluster::O-antigen cluster of S. flexneri 2457 T, araBAD::cat) (provided by GlycoVaxyn AG, Schlieren, Switzerland) harboring the O-antigen cluster of S. flexneri 2a under control of its native (constitutive) promoter on the genome was used as the production strain for all in vivo glycosylation experiments in this study. This strain also carries a genomic integration of the gene encoding glucosyltransferase GtrII, which attaches a glucose branch to the middle rhamnose residues essential for proper immune response, at the gtrS locus. The oligosaccharyltransferase PglB from C. jejuni was expressed from a spectinomycin-selectable, low-copy number expression plasmid (backbone pEXT21 , origin of replication IncW) under control of the IPTG-inducible hybrid promoter Ptac. The PglB sequence was codon-optimized for expression in E. coli by gene synthesis (GenScript, Piscataway, NJ, USA). A glycosylation deficient PglB variant (PglBmut) harboring two point mutations (W458A and D459A) was used as negative control. For Western blot detection a hemagglutinin oligopeptide tag (HA) was genetically fused to the C-terminal end of the corresponding PglB sequences. As carrier protein, a detoxified version of P. aeruginosa exotoxin A (EPA, L552V, ΔE553) containing two engineered N-glycosylation sites (N262 and N398) was expressed from an ampicillin-resistant, high-copy number plasmid under control of the arabinose-inducible promoter ParaBAD (pEC415 ). For Sec-dependent secretion to the periplasm a DsbA signal peptide was genetically fused at the N-teminal end of EPA.
Expression of EPA-2a in shake flasks
Small scale recombinant expression of the glycoconjugate vaccine EPA-2a was performed in 100 ml Erlenmeyer flasks (without baffles) filled with 50 ml medium. The complex medium used in this study was composed of 10 g/L yeast extract (Bacto yeast extract, BD, Le Pont de Claix, France), 20 g/L soy peptone (soy peptone A3 SC, Organotechnie, La Courneuve, France), 9 g/L KH2PO4, 5 g/L (NH4)2SO4, 1 g/L citric acid, 4 g/L glycerol, 10 mM MgSO4 and 10 ml/L trace element solution (10 g/L CaCo3, 20 g/L FeCl3*6 H2O, 1.5 g/L MnCl2*4 H2O, 0.3 g/L H3BO3, 0.25 g/L CoCl2*6 H2O, 0.15 g/L CuSO4, 0.5 g/L ZnCl2, 2 g/L NaMoO4, 84.4 g/L Na4EDTA*2 H2O, 20 ml/L, 37% HCl). To maintain plasmid stability the medium was supplemented with 100 μg/ml ampicillin and 80 μg/ml spectinomycin. Shake flasks were inoculated from overnight tube cultures to a starting OD600 value of 0.08 and incubated at 30°C and 160 rpm until cultures reached an OD600 of 0.6 – 0.8. PglB expression was induced by the addition of 1 mM IPTG, and the protein carrier EPA was induced by the addition of 2 g/L arabinose. For sequential induction, IPTG was added at an OD600 of 0.6 – 0.8 and 2 h later 2 g/L arabinose was added (if not stated otherwise). N-acetylglucosamine was always added concomitantly with IPTG. Induced bacteria cells were incubated over night before harvesting by centrifugation (6500 × g, 5 min, 4°C).
Cultivation in 96-deep well plates
For screening of parameters that influence EPA-2a production, recombinant E. coli cells were grown in 96-deep well plates (DWPs) (VWR, order No. 732–0585) in 1.6 ml of the same medium used for shake flask cultures. DWPs were inoculated with an uninduced overnight shake flask culture to a starting OD600 of 0.05 – 0.1 and incubated at 30°C and 500 rpm in a specialized microplate incubator (Infors HT Microton, Bottmingen, Switzerland). When cultures reached an OD600 of 0.4 – 0.6, PglB and EPA expression was induced by adding 1 mM IPTG and 2 g/L arabinose respectively. N-acetylglucosamine was added simultaneously with IPTG (similar to shake flask experiments). After overnight incubation, 900 μl culture per well were transferred with a multi-channel pipette to a new DWP and harvested by centrifugation (1600 × g, 10 min, 4°C). Supernatant was withdrawn with a multi-channel pipette and periplasmic extracts were prepared as described below.
Optimization studies of high-cell density cultures were carried out in a 4-parallel bioreactor system (Infors HT, Multifors 2, Bottmingen, Switzerland) with a total vessel volume of 1 L. The composition of the complex medium was the same as described in the shake flask section, except that the initial carbon concentration was increased to 25 g/L glycerol. MgSO4, trace element solution and antibiotics were sterilized separately and added after autoclaving. The feeding solution consisted of 33 g/L yeast extract (Bacto yeast extract, BD, Le Pont de Claix, France), 67 g/L soy peptone (soy peptone A3 SC, Organotechnie, La Courneuve, France), 250 g/L glycerol, 10 mM MgSO4 and 10 ml/L trace element solution. The initial batch culture was started by inoculation of 0.5 L medium with an overnight seed culture to a final starting OD600 of 0.05. The pH was adjusted to 7.00+/−0.05 by the addition of 25% H3PO4 and 4 M KOH. Dissolved oxygen levels (DO2) were kept at 30% saturation by automated-enriching of the inlet air with pure oxygen. Bioreactors were stirred at 1000 rpm during the whole bioprocess. Foam formation was inhibited by the manual addition of the anti-foaming agent Antifoam 204 (Sigma-Aldrich, Buchs, Switzerland). PglB and EPA expression were induced by addition of 1 mM IPTG and 2 g/L arabinose, respectively. After induction, inducers were also added to the feed solution (concentration in feed: 1 mM IPTG, 2 g/L arabinose) to ensure their constant concentrations in the culture broth. Cell growth was monitored during the whole process by measuring the optical density (OD) at 600 nm using a UV-visible spectrophotometer (Genesys 6, ThermoSpectronic, Lausanne, Switzerland). Culture samples were diluted with deionized H2O until the final OD600 value was less than 0.4.
Preparation of periplasmic extracts
In order to determine the specific productivity of glycoprotein production under altered conditions periplasmic proteins were isolated by an osmotic shock method . In brief, cells corresponding to 2 (or 10) OD600 units were harvested by centrifugation at 6500 × g for 5 minutes and 4°C. Subsequently cell pellets were resuspended in 200 μl (or 1 ml) of chilled sucrose-lysozyme buffer (30 mM Tris–HCl pH 8, 20% w/v sucrose, 1 mM EDTA, 1 mg/ml lysozyme and complete protease inhibitor mix (Roche, Basel, Switzerland)) to a final OD600 of 10 and incubated on ice for 30 minutes. Periplasmic proteins were separated from cell debris and protoplasts by centrifugation at 6500 × g for 10 minutes at 4°C, and supernatant was withdrawn and stored at −20°C until further analysis.
Enzyme-linked immunosorbent assay (ELISA)
For quantification of relative glycoconjugate yields in periplasmic extracts a sandwich ELISA was applied in a 96-well format (F96 MaxiSorp, Nunc). As capture antibody, protein G purified goat-anti-EPA antiserum (US Biological/Lucerna Chem AG, Lucerne, Switzerland) was diluted with 1 × PBS to a final concentration of 10 μg/ml, and microtiter plate wells were coated with 60 μl of capture antibody solution at 4°C overnight. All subsequent incubation steps were performed at room temperature. After four washing steps with 300 μl washing buffer PBST (1 × PBS, 0.05% Tween) separated by a 2 minutes incubation period under vigorous shaking using an automated microplate washer (Wellwash Versa, Thermo-Scientific, Zurich, Switzerland) wells were blocked for 2 h with 300 μl blocking solution (1 × PBS, 10% dry milk) followed by another washing procedure as described above. Subsequently, periplasmic extracts containing glycoproteins were diluted with dilution buffer (1 × PBS, 1% dry milk) to appropriate final dilutions of 1:100, 1:1000 or 1:10000, respectively, and 50 μl diluted periplasmic extracts were applied to ELISA plates and incubated for 1 h thereby allowing the antigen EPA to bind to the capture antibody. Unbound EPA-2a and unbound, unglycosylated EPA carrier protein were removed by four washing cycles with 300 μl washing buffer per well. Next 50 μl of a specific polyclonal antibody against the S. flexneri 2a polysaccharide chain developed in rabbit (rabbit-anti-2a; GVXN#92, GlycoVaxyn AG, Schlieren, Switzerland) were added as a 1:10000 dilution in 1 × PBS + 1% dry milk to the wells. After a 1 h incubation, plates were washed four times with washing buffer PBST to remove residual anti-2a antibody and probed for another hour with 50 μl of a 1:20000 dilution in 1 × PBS + 1% dry milk of the peroxidase-coupled detection antibody (goat anti-rabbit IgG-HRP, Bio-Rad, Reinach, Switzerland). Four final washing steps were performed before ELISA signals were developed with 100 μl Ultra-TMB-ELISA HRP substrate (Thermo-Scientific Pierce). The color reaction was stopped by addition of 100 μl of 1 N H2SO4 per well, and absorbance was measured in a 96-well photometer (BioTek, Synergy Mx, Lucerne, Switzerland) at 450 nm. The obtained A450 values allowed the relative comparison of EPA-2a in periplasmic extracts on the same plate. The highest A450 value was subsequently normalized to 1.
Western blot analysis
Periplasmic extracts (5 μl) were supplemented by equal volumes of 2 × SDS-PAGE sample buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromphenol blue, 0.125 M Tris HCl) and denatured at 95°C for 5 minutes. Samples were analyzed by 8% SDS-PAGE and transferred on a nitrocellulose membrane using the iBlot blotting system (Invitrogen, Carlsbad, USA). After blocking with 1 × PBS 10% milk for 1 h, membranes were probed with either rabbit anti-EPA antiserum (Sigma-Aldrich, Buchs, Switzerland) or rabbit anti-2a antiserum (GVXN#92, GlycoVaxyn AG, Schlieren, Switzerland), both applied as 1:20000 dilution in 1 × PBS 1% dry milk for 1 h. Prior to ECL-based chemiluminescent detection of EPA-2a glycoconjugates (ChemiDoc-It, UVP, Upland, USA) the membranes were hybridized with a peroxidase-coupled secondary antibody (goat anti-rabbit IgG-HRP, Bio-Rad, Reinach, Switzerland, 1:20000 in 1 × PBS 1% dry milk).
This work was supported by the SNF SSAJRP Research Program from the University of Basel (SMC JRP 03).
- Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ. 1999;77(8):651–66.Google Scholar
- Niyogi SK. Shigellosis. J Microbiol. 2005;43(2):133–43.Google Scholar
- Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol. 2007;5(7):540–53.View ArticleGoogle Scholar
- Ranallo RT, Fonseka S, Boren TL, Bedford LA, Kaminski RW, Thakkar S, et al. Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates. Vaccine. 2012;30(34):5159–71.View ArticleGoogle Scholar
- Barman S, Koley H, Ramamurthy T, Chakrabarti MK, Shinoda S, Nair GB, et al. Protective immunity by oral immunization with heat-killed Shigella strains in a guinea pig colitis model. Microbiol Immunol. 2013;57(11):762–71.View ArticleGoogle Scholar
- Martinez-Becerra FJ, Chen X, Dickenson NE, Choudhari SP, Harrison K, Clements JD, et al. Characterization of a novel fusion protein of IpaB and IpaD of Shigella and its potential as a pan-Shigella vaccine. Infect Immun. 2013;81(12):4470–7.View ArticleGoogle Scholar
- Pore D, Mahata N, Pal A, Chakrabarti MK. Outer membrane protein A (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model. PLoS One. 2011;6(7):e22663.View ArticleGoogle Scholar
- Riddle MS, Kaminski RW, Williams C, Porter C, Baqar S, Kordis A, et al. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine. Vaccine. 2011;29(40):7009–19.View ArticleGoogle Scholar
- Phalipon A, Tanguy M, Grandjean C, Guerreiro C, Belot F, Cohen D, et al. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. J Immunol. 2009;182(4):2241–7.View ArticleGoogle Scholar
- Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydr Res. 2003;338:2539–47.View ArticleGoogle Scholar
- Avci FY, Kasper DL. How Bacterial Carbohydrates Influence the Adaptive Immune System. Annu Rev Immunol. 2010;28:107–30.View ArticleGoogle Scholar
- Cohen D, Ashkenazi S, Green M, Lerman Y, Slepon R, Robin G, et al. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect Immun. 1996;64(10):4074–7.Google Scholar
- Frasch CE. Preparation of bacterial polysaccharide-protein conjugates: analytical and manufacturing challenges. Vaccine. 2009;27(46):6468–70.View ArticleGoogle Scholar
- Wacker M, Linton D, Hitchen PG, Nita-Lazar M, Haslam SM, North SJ, et al. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science. 2002;298(5599):1790–3.View ArticleGoogle Scholar
- Wacker M, Feldman MF, Callewaert N, Kowarik M, Clarke BR, Pohl NL, et al. Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems. Proc Natl Acad Sci USA. 2006;103(18):7088–93.View ArticleGoogle Scholar
- Kowarik M, Young NM, Numao S, Schulz BL, Hug I, Callewaert N, et al. Definition of the bacterial N-glycosylation site consensus sequence. EMBO Journal. 2006;25(9):1957–66.View ArticleGoogle Scholar
- Cuccui J, Thomas RM, Moule MG, D'Elia RV, Laws TR, Mills DC, et al. Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis. Open Biol. 2013;3(5):130002.View ArticleGoogle Scholar
- Ihssen J, Kowarik M, Dilettoso S, Tanner C, Wacker M, Thöny-Meyer L. Production of glycoprotein vaccines in Escherichia coli. Microb Cell Fact. 2010;9:61.View ArticleGoogle Scholar
- Iwashkiw JA, Fentabil MA, Faridmoayer A, Mills DC, Peppler M, Czibener C, et al. Exploiting the Campylobacter jejuni protein glycosylation system for glycoengineering vaccines and diagnostic tools directed against brucellosis. Microb Cell Fact. 2012;11:13.View ArticleGoogle Scholar
- Wetter M, Kowarik M, Steffen M, Carranza P, Corradin G, Wacker M. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component. Glycoconj J. 2013;30(5):511–22.View ArticleGoogle Scholar
- Pandhal J, Woodruff LB, Jaffe S, Desai P, Ow SY, Noirel J, et al. Inverse metabolic engineering to improve Escherichia coli as an N-glycosylation host. Biotechnol Bioeng. 2013;110(9):2482–93.View ArticleGoogle Scholar
- Pandhal J, Desai P, Walpole C, Doroudi L, Malyshev D, Wright PC. Systematic metabolic engineering for improvement of glycosylation efficiency in Escherichia coli. Biochem Biophys Res Commun. 2012;419(3):472–6.View ArticleGoogle Scholar
- Pandhal J, Ow SY, Noirel J, Wright PC. Improving N-glycosylation efficiency in Escherichia coli using shotgun proteomics, metabolic network analysis, and selective reaction monitoring. Biotechnol Bioeng. 2011;108(4):902–12.View ArticleGoogle Scholar
- Choi JH, Keum KC, Lee SY. Production of recombinant proteins by high cell density culture of Escherichia coli. Chemical Engineering Science. 2006;61(3):876–85.View ArticleGoogle Scholar
- Lee SY. High cell-density culture of Escherichia coli. Trends Biotechnol. 1996;14(3):98–105.View ArticleGoogle Scholar
- Terra VS, Mills DC, Yates LE, Abouelhadid S, Cuccui J, Wren BW. Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design. J Med Microbiol. 2012;61:919–26.View ArticleGoogle Scholar
- Lindberg AA, Karnell A, Weintraub A. The lipopolysaccharide of Shigella bacteria as a virulence factor. Rev Infect Dis. 1991;13 Suppl 4:S279–84.View ArticleGoogle Scholar
- Wagner A, Stiegler G, Vorauer-Uhl K, Katinger H, Quendler H, Hinz A, et al. One step membrane incorporation of viral antigens as a vaccine candidate against HIV. J Liposome Res. 2007;17:139–54.View ArticleGoogle Scholar
- Wagner S, Bader ML, Drew D, de Gier JW. Rationalizing membrane protein overexpression. Trends Biotechnol. 2006;24:364–71.View ArticleGoogle Scholar
- Purvis JE, Yomano LP, Ingram LO. Enhanced trehalose production improves growth of Escherichia coli under osmotic stress. Appl Environ Microbiol. 2005;71(7):3761–9.View ArticleGoogle Scholar
- Joseph TC, Rajan LA, Thampuran N, James R. Functional characterization of trehalose biosynthesis genes from E. coli: an osmolyte involved in stress tolerance. Mol Biotechnol. 2010;46(1):20–5.View ArticleGoogle Scholar
- Strom AR, Kaasen I. Trehalose metabolism in Escherichia coli: stress protection and stress regulation of gene expression. Mol Microbiol. 1993;8(2):205–10.View ArticleGoogle Scholar
- Gerber S, Lizak C, Michaud G, Bucher M, Darbre T, Aebi M, et al. Mechanism of bacterial oligosaccharyltransferase: in vitro quantification of sequon binding and catalysis. J Biol Chem. 2013;288(13):8849–61.View ArticleGoogle Scholar
- Sharma CB, Lehle L, Tanner W. N-Glycosylation of yeast proteins. Characterization of the solubilized oligosaccharyl transferase. Eur J Biochem. 1981;116(1):101–8.View ArticleGoogle Scholar
- Lizak C, Gerber S, Numao S, Aebi M, Locher KP. X-ray structure of a bacterial oligosaccharyltransferase. Nature. 2011;474(7351):350–5.View ArticleGoogle Scholar
- Jeong KJ, Lee SY. High-level production of human leptin by fed-batch cultivation of recombinant Escherichia coli and its purification. Appl Environ Microbiol. 1999;65(7):3027–32.Google Scholar
- Chen MM, Glover KJ, Imperiali B. From peptide to protein: comparative analysis of the substrate specificity of N-linked glycosylation in C. jejuni. Biochemistry. 2007;46(18):5579–85.View ArticleGoogle Scholar
- Feldman MF, Wacker M, Hernandez M, Hitchen PG, Marolda CL, Kowarik M, et al. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci USA. 2005;102(8):3016–21.View ArticleGoogle Scholar
- Wacker M, Wang L, Kowarik M, Dowd M, Lipowsky G, Faridmoayer A, et al. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli. J Infect Dis. 2014;209(10):1551–61.View ArticleGoogle Scholar
- Dmitriev BA, Knirel YA, Kochetkov NK, Hofman IL. Somatic antigens of Shigella - structural investigation on o-specific polysaccharide chain of Shigella dysenteriae type-1 lipopolysaccharide. Eur J Biochem. 1976;66(3):559–66.View ArticleGoogle Scholar
- Lvov VL, Shashkov AS, Dmitriev BA, Kochetkov NK, Jann B, Jann K. Structural studies of the o-specific side-chain of the lipopolysaccharide from Escherichia coli o-7. Carbohydr Res. 1984;126(2):249–59.View ArticleGoogle Scholar
- Collins T, Azevedo-Silva J, da Costa A, Branca F, Machado R, Casal M. Batch production of a silk-elastin-like protein in E. coli BL21 (DE3): key parameters for optimisation. Microb Cell Fact. 2013;12:21.View ArticleGoogle Scholar
- Lecina M, Sarro E, Casablancas A, Godia F, Cairo JJ. IPTG limitation avoids metabolic burden and acetic acid accumulation in induced fed-batch cultures of Escherichia coli M15 under glucose limiting conditions. Biochem Eng J. 2013;70:78–83.View ArticleGoogle Scholar
- Pinsach J, de Mas C, Lopez-Santin J. Induction strategies in fed-batch cultures for recombinant protein in Escherichia coli: Application to rhamnulose 1-phosphate aldolase. Biochem Eng J. 2008;41(2):181–7.View ArticleGoogle Scholar
- Carneiro S, Ferreira EC, Rocha I. Metabolic responses to recombinant bioprocesses in Escherichia coli. J Biotechnol. 2013;164(3):396–408.View ArticleGoogle Scholar
- Hoffmann F, Rinas U. Stress induced by recombinant protein production in Escherichia coli. Adv Biochem Eng Biotechnol. 2004;89:73–92.Google Scholar
- Neubauer P, Lin HY, Mathiszik B. Metabolic load of recombinant protein production: Inhibition of cellular capacities for glucose uptake and respiration after induction of a heterologous gene in Escherichia coli. Biotechnol Bioeng. 2003;83(1):53–64.View ArticleGoogle Scholar
- Bentley WE, Kompala DS. Optimal induction of protein-synthesis in recombinant bacterial cultures. Ann N Y Acad Sci. 1990;589:121–38.View ArticleGoogle Scholar
- Dalbey RE, Wang P, Kuhn A. Assembly of bacterial inner membrane proteins. Annu Rev Biochem. 2011;80:161–87.View ArticleGoogle Scholar
- Konopka JB. N-acetylglucosamine (GlcNAc) functions in cell signaling. Scientifica (Cairo) 2012;Article ID 489208.Google Scholar
- Amer AO, Valvano MA. Conserved aspartic acids are essential for the enzymic activity of the WecA protein initiating the biosynthesis of O-specific lipopolysaccharide and enterobacterial common antigen in Escherichia coli. Microbiology. 2002;148(Pt 2):571–82.Google Scholar
- Yao Z, Valvano MA. Genetic analysis of the O-specific lipopolysaccharide biosynthesis region (rfb) of Escherichia coli K-12 W3110: identification of genes that confer group 6 specificity to Shigella flexneri serotypes Y and 4a. J Bacteriol. 1994;176(13):4133–43.Google Scholar
- Dutka-Malen S, Mazodier P, Badet B. Molecular cloning and overexpression of the glucosamine synthetase gene from Escherichia coli. Biochimie. 1988;70(2):287–90.View ArticleGoogle Scholar
- Mengin-Lecreulx D, van Heijenoort J. Characterization of the essential gene glmM encoding phosphoglucosamine mutase in Escherichia coli. J Biol Chem. 1996;271(1):32–9.View ArticleGoogle Scholar
- Mengin-Lecreulx D, van Heijenoort J. Copurification of glucosamine-1-phosphate acetyltransferase and N-acetylglucosamine-1-phosphate uridyltransferase activities of Escherichia coli: characterization of the glmU gene product as a bifunctional enzyme catalyzing two subsequent steps in the pathway for UDP-N-acetylglucosamine synthesis. J Bacteriol. 1994;176(18):5788–95.Google Scholar
- Milewski S. Glucosamine-6-phosphate synthase–the multi-facets enzyme. Biochim Biophys Acta. 2002;1597(2):173–92.View ArticleGoogle Scholar
- Rogers MJ, Ohgi T, Plumbridge J, Soll D. Nucleotide sequences of the Escherichia coli nagE and nagB genes: the structural genes for the N-acetylglucosamine transport protein of the bacterial phosphoenolpyruvate: sugar phosphotransferase system and for glucosamine-6-phosphate deaminase. Gene. 1988;62(2):197–207.View ArticleGoogle Scholar
- Sasai K, Ikeda Y, Fujii T, Tsuda T, Taniguchi N. UDP-GlcNAc concentration is an important factor in the biosynthesis of beta1,6-branched oligosaccharides: regulation based on the kinetic properties of N-acetylglucosaminyltransferase V. Glycobiology. 2002;12(2):119–27.View ArticleGoogle Scholar
- Al-Dabbagh B, Mengin-Lecreulx D, Bouhss A. Purification and characterization of the bacterial UDP-GlcNAc:undecaprenyl-phosphate GlcNAc-1-phosphate transferase WecA. J Bacteriol. 2008;190(21):7141–6.View ArticleGoogle Scholar
- Liu B, Knirel YA, Feng L, Perepelov AV, Senchenkova SN, Wang Q, et al. Structure and genetics of Shigella O antigens. FEMS Microbiol Rev. 2008;32(4):627–53.View ArticleGoogle Scholar
- Lehane AM, Korres H, Verma NK. Bacteriophage-encoded glucosyltransferase GtrII of Shigella flexneri: membrane topology and identification of critical residues. Biochem J. 2005;389(Pt 1):137–43.Google Scholar
- Igura M, Maita N, Kamishikiryo J, Yamada M, Obita T, Maenaka K, et al. Structure-guided identification of a new catalytic motif of oligosaccharyltransferase. EMBO J. 2008;27(1):234–43.View ArticleGoogle Scholar
- Welply JK, Shenbagamurthi P, Lennarz WJ, Naider F. Substrate recognition by oligosaccharyltransferase. Studies on glycosylation of modified Asn-X-Thr/Ser tripeptides. J Biol Chem. 1983;258(19):11856–63.Google Scholar
- Riesenberg D, Schulz V, Knorre WA, Pohl HD, Korz D, Sanders EA, et al. High cell density cultivation of Escherichia coli at controlled specific growth rate. J Biotechnol. 1991;20(1):17–27.View ArticleGoogle Scholar
- Dykxhoorn DM, St Pierre R, Linn T. A set of compatible tac promoter expression vectors. Gene. 1996;177(1–2):133–6.View ArticleGoogle Scholar
- Ihssen J, Kowarik M, Wiesli L, Reiss R, Wacker M, Thöny-Meyer L. Structural insights from random mutagenesis of Campylobacter jejuni oligosaccharyltransferase PglB. Bmc Biotechnol. 2012;12:67.View ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.